Login / Signup

COVID-19 vaccine efficacy in participants with weakened immune systems from four randomized-controlled trials.

Amy C ShermanJessica TuanValeria D CantosOladunni AdeyigaScott MahoneyAna M Ortega-VillaAmy TillmanJennifer WhitakerAmanda S Woodward DavisBrett LeavIan HirschJerald SadoffLisa M DunklePeter B GilbertHolly E JanesJames G KublinPaul A GoepfertKaren KotloffNadine RouphaelAnn R FalseyHana M El SahlyMagdalena E SobieszczykYunda HuangKathleen M NeuzilLawrence CoreyBeatriz GrinsztejnGlenda GrayMartha NasonLindsey R BadenCynthia L Gay
Published in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024)
For individuals with mildly immunocompromising conditions, there is no evidence of differences in VE against symptomatic or severe COVID-19 compared to those with non-tempered immune systems in the four COVID-19 vaccine randomized controlled efficacy trials.
Keyphrases
  • coronavirus disease
  • sars cov
  • randomized controlled trial
  • respiratory syndrome coronavirus
  • open label
  • double blind
  • phase iii
  • systematic review